ATE349465T1 - Zusammensetzungen sowie verfahren zur hocheffizienten transfektion - Google Patents

Zusammensetzungen sowie verfahren zur hocheffizienten transfektion

Info

Publication number
ATE349465T1
ATE349465T1 AT98904264T AT98904264T ATE349465T1 AT E349465 T1 ATE349465 T1 AT E349465T1 AT 98904264 T AT98904264 T AT 98904264T AT 98904264 T AT98904264 T AT 98904264T AT E349465 T1 ATE349465 T1 AT E349465T1
Authority
AT
Austria
Prior art keywords
methods
polypeptide
compositions
highly efficient
efficient transfection
Prior art date
Application number
AT98904264T
Other languages
English (en)
Inventor
Adrian Mark Haines
Ross Owen Phillips
John Hamilton Welsh
David Robert Thatcher
Alistair Simpson Irvine
Original Assignee
Innovata Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1997/000396 external-priority patent/WO1997028818A1/en
Application filed by Innovata Plc filed Critical Innovata Plc
Application granted granted Critical
Publication of ATE349465T1 publication Critical patent/ATE349465T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT98904264T 1997-02-12 1998-02-12 Zusammensetzungen sowie verfahren zur hocheffizienten transfektion ATE349465T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB1997/000396 WO1997028818A1 (en) 1996-02-12 1997-02-12 Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US86143297A 1997-05-21 1997-05-21
US5565797P 1997-08-14 1997-08-14

Publications (1)

Publication Number Publication Date
ATE349465T1 true ATE349465T1 (de) 2007-01-15

Family

ID=27268662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904264T ATE349465T1 (de) 1997-02-12 1998-02-12 Zusammensetzungen sowie verfahren zur hocheffizienten transfektion

Country Status (6)

Country Link
EP (1) EP1007549B1 (de)
JP (1) JP2001512312A (de)
AT (1) ATE349465T1 (de)
AU (1) AU749113B2 (de)
DE (1) DE69836746D1 (de)
WO (1) WO1998035984A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771111B2 (en) 1998-07-21 2004-03-11 Emd Millipore Corporation A polynucleotide comprising a ubiquitous chromatin opening element (UCOE)
AU5612199A (en) * 1998-09-10 2000-04-03 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other
MXPA02008637A (es) 2000-03-02 2004-09-06 Ml Lab Plc Elemento de respuesta a factor de celulas t.
EP1294908B1 (de) * 2000-06-28 2006-03-08 Max-Delbrück-Centrum Für Molekulare Medizin Verfahren zur verbesserung der transfektionseffizienz
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6568594A (en) * 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
EP0831922A2 (de) * 1995-06-08 1998-04-01 Therexsys Limited Verwendung virus-ähnlicher partikel in der gentherapie

Also Published As

Publication number Publication date
EP1007549A1 (de) 2000-06-14
EP1007549B1 (de) 2006-12-27
WO1998035984A2 (en) 1998-08-20
JP2001512312A (ja) 2001-08-21
DE69836746D1 (de) 2007-02-08
AU6221198A (en) 1998-09-08
WO1998035984A3 (en) 1999-01-07
AU749113B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
BR9607383A (pt) Composição farmacêutica útil para a transfecção de um ácido nucléico e utilização desta composição
PT1326634E (pt) Composicao de vacina compreendendo um antigenio e um peptido possuindo propriedades adjuvantes
EA199900355A1 (ru) Теломераза обратная тринскриптаза
NZ270659A (en) Mammalian protein which binds to a gst-fkbp-rapamycin complex, dna therefor and diagnostic compositions
IL144989A0 (en) Method for acylating peptides and novel acylating agents
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
EA200000605A1 (ru) Гидрофобно модифицированные композиции белков и способы
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
BR9811592A (pt) Oxidase de citocinina
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
ATE349465T1 (de) Zusammensetzungen sowie verfahren zur hocheffizienten transfektion
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
BR9713632A (pt) Citocina de mamìfero relacionada com a il-10
DE69315730D1 (de) Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
Fisher et al. Myoglobins of cartilaginous fishes III. Amino acid sequence of myoglobin of the shark Galeorhinus australis
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties